Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus

Paper describes use of daratumumab, a monoclonal antibody that targets CD38, to induce substantial clinical responses in 2 patients with life-threatening lupus, with the clinical responses sustained by maintenance therapy with belimumab, an antibody to B-cell activating factor.


New England Journal of Medicine